Cancers, Vol. 12, Pages 3380: Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling

Alexandros G.Sfakianakis shared this article with you from Inoreader Cancers, Vol. 12, Pages 3380: Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling Μέσω Cancers Cancers, Vol. 12, Pages 3380: Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling Cancers doi: 10.3390/cancers12113380 Authors: Antonio Giovanni Solimando Simona De Summa Angelo Vacca Domenico Ribatti Cancer-associated neo vessels’ formation acts as a gatekeeper that orchestrates the entrance and egress of patrolling immune cells within the tumor milieu. This is achieved, in part, via the directed chemokines’ expression and cell adhesion molecules on the endothelial cell surface that attract and retain circulating leukocytes. The crosstalk between adaptive immune cells and the cancer endothelium is thus essential for tumor immune surveillance and the success of immune-based therapies that harness immune cells to kill tumor cells. This review will focus on the biology of the endothelium and will explore the vascular-specific molecular mediators that control the recruitment, retention, and trafficking of immune cells that are essential for effective antitumor immunity. The literature revision will also explore how abnormalities in the tumor endothelium impair crosstalk with adaptive immune cells and how targeting these abnormalities can improve the success of immune-based therapies for different malignancies, with a particular focus on the paradigmatic example represented by multiple myeloma. We also generated and provide two original bio-informatic analyses, in order to sketch the physiopathology underlying the endothelial–neoplastic interactions in an easier manner, feeding into a vicious cycle propagating disease progression and highlighting novel pathways that might be exploited therapeutically. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.